CureVac N.V. (5CV.F)
EUR 2.72
(-2.01%)
EUR 2.72
(-2.01%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -70.6 Million EUR | 21.87% |
| 2022 | -116.57 Million EUR | 13.78% |
| 2021 | -135.2 Million EUR | -489.34% |
| 2020 | 34.72 Million EUR | 428.64% |
| 2019 | -10.56 Million EUR | -116.85% |
| 2018 | -4.87 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -31.22 Million EUR | 10.33% |
| 2024 Q1 | -29.31 Million EUR | 22.39% |
| 2023 Q2 | -18.27 Million EUR | -35.31% |
| 2023 FY | -91.07 Million EUR | 21.87% |
| 2023 Q1 | -13.5 Million EUR | 80.23% |
| 2023 Q4 | -37.77 Million EUR | -384.42% |
| 2023 Q3 | -7.79 Million EUR | 57.33% |
| 2022 Q3 | -12.86 Million EUR | 42.9% |
| 2022 Q2 | -22.53 Million EUR | -75.25% |
| 2022 Q1 | -12.85 Million EUR | 55.34% |
| 2022 FY | -116.57 Million EUR | 13.78% |
| 2022 Q4 | -68.31 Million EUR | -430.91% |
| 2021 Q1 | -5.73 Million EUR | -409.79% |
| 2021 Q3 | -85.68 Million EUR | -471.17% |
| 2021 Q2 | -15 Million EUR | -161.8% |
| 2021 FY | -135.2 Million EUR | -489.34% |
| 2021 Q4 | -28.79 Million EUR | 66.4% |
| 2020 Q4 | -1.12 Million EUR | -135.25% |
| 2020 Q3 | 3.18 Million EUR | -90.66% |
| 2020 Q2 | 34.15 Million EUR | 1549.49% |
| 2020 Q1 | -2.35 Million EUR | -2.66% |
| 2020 FY | 34.72 Million EUR | 428.64% |
| 2019 Q1 | -4.4 Million EUR | 0.0% |
| 2019 Q3 | -5.9 Million EUR | 0.0% |
| 2019 FY | -10.56 Million EUR | -116.85% |
| 2019 Q4 | -2.29 Million EUR | 61.12% |
| 2018 FY | -4.87 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| BioNTech SE | 3.21 Billion EUR | 102.193% |
| Biotest Aktiengesellschaft | 271.9 Million EUR | 125.968% |
| Biotest Aktiengesellschaft | 271.9 Million EUR | 125.968% |
| BRAIN Biotech AG | 30.12 Million EUR | 334.407% |
| Formycon AG | 23.3 Million EUR | 402.974% |
| Heidelberg Pharma AG | 6.6 Million EUR | 1168.833% |
| Medigene AG | 4.39 Million EUR | 1708.016% |